S&P 500   3,338.33 (-0.32%)
DOW   27,332.54 (-0.20%)
QQQ   269.41 (-1.90%)
AAPL   443.47 (-2.66%)
MSFT   211.52 (-2.23%)
FB   266.12 (+0.32%)
GOOGL   1,491.28 (-0.91%)
AMZN   3,157.71 (-2.09%)
NVDA   443.05 (-2.29%)
CGC   16.74 (-4.45%)
BABA   250.21 (-5.82%)
TSLA   1,427.69 (-4.15%)
MU   48.24 (-0.94%)
GE   6.42 (+1.42%)
AMD   83.74 (-3.43%)
T   29.97 (+0.44%)
F   6.84 (-1.30%)
ACB   10.09 (-2.13%)
GILD   69.00 (+0.28%)
NFLX   489.60 (-3.83%)
DIS   129.32 (-1.15%)
BAC   26.05 (+2.28%)
BA   169.02 (-1.85%)
S&P 500   3,338.33 (-0.32%)
DOW   27,332.54 (-0.20%)
QQQ   269.41 (-1.90%)
AAPL   443.47 (-2.66%)
MSFT   211.52 (-2.23%)
FB   266.12 (+0.32%)
GOOGL   1,491.28 (-0.91%)
AMZN   3,157.71 (-2.09%)
NVDA   443.05 (-2.29%)
CGC   16.74 (-4.45%)
BABA   250.21 (-5.82%)
TSLA   1,427.69 (-4.15%)
MU   48.24 (-0.94%)
GE   6.42 (+1.42%)
AMD   83.74 (-3.43%)
T   29.97 (+0.44%)
F   6.84 (-1.30%)
ACB   10.09 (-2.13%)
GILD   69.00 (+0.28%)
NFLX   489.60 (-3.83%)
DIS   129.32 (-1.15%)
BAC   26.05 (+2.28%)
BA   169.02 (-1.85%)
S&P 500   3,338.33 (-0.32%)
DOW   27,332.54 (-0.20%)
QQQ   269.41 (-1.90%)
AAPL   443.47 (-2.66%)
MSFT   211.52 (-2.23%)
FB   266.12 (+0.32%)
GOOGL   1,491.28 (-0.91%)
AMZN   3,157.71 (-2.09%)
NVDA   443.05 (-2.29%)
CGC   16.74 (-4.45%)
BABA   250.21 (-5.82%)
TSLA   1,427.69 (-4.15%)
MU   48.24 (-0.94%)
GE   6.42 (+1.42%)
AMD   83.74 (-3.43%)
T   29.97 (+0.44%)
F   6.84 (-1.30%)
ACB   10.09 (-2.13%)
GILD   69.00 (+0.28%)
NFLX   489.60 (-3.83%)
DIS   129.32 (-1.15%)
BAC   26.05 (+2.28%)
BA   169.02 (-1.85%)
S&P 500   3,338.33 (-0.32%)
DOW   27,332.54 (-0.20%)
QQQ   269.41 (-1.90%)
AAPL   443.47 (-2.66%)
MSFT   211.52 (-2.23%)
FB   266.12 (+0.32%)
GOOGL   1,491.28 (-0.91%)
AMZN   3,157.71 (-2.09%)
NVDA   443.05 (-2.29%)
CGC   16.74 (-4.45%)
BABA   250.21 (-5.82%)
TSLA   1,427.69 (-4.15%)
MU   48.24 (-0.94%)
GE   6.42 (+1.42%)
AMD   83.74 (-3.43%)
T   29.97 (+0.44%)
F   6.84 (-1.30%)
ACB   10.09 (-2.13%)
GILD   69.00 (+0.28%)
NFLX   489.60 (-3.83%)
DIS   129.32 (-1.15%)
BAC   26.05 (+2.28%)
BA   169.02 (-1.85%)
Log in

ASX:CDYCellmid Stock Price, Forecast & News

Add
Compare
Today's Range N/A
50-Day Range
A$0.19
MA: A$0.18
A$0.19
52-Week Range N/A
VolumeN/A
Average VolumeN/A
Market Capitalization$17.87 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Cellmid Limited, a life sciences company, develops and commercializes diagnostic and therapeutic products for cancer and various chronic inflammatory conditions in Australia, the United States, and Japan. The company offers Midkine (MK) ELISA Kit, a cancer biomarker, and diagnostic and prognostic tool. It is also developing CAB102, a humanized monoclonal antibody for use in solid tumors; CAB101, a monoclonal antibody for the treatment of kidney injury, and inflammatory and fibrotic diseases; and CMK103, a recombinant human form of MK protein for use in cardiac ischemia. In addition, the company develops and sells over-the-counter products; and develops and markets a range of FGF5 inhibitor hair growth products under the evolis name. As of November 01, 2018, it operated 17 stores and through online, which offers the évolis professional products in the United States. Cellmid Limited is based in Sydney, Australia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.08 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone61 2 9221 6830

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$7.65 million
Book ValueA$0.07 per share

Profitability

Miscellaneous

EmployeesN/A
Market Cap$17.87 million
Next Earnings DateN/A
OptionableNot Optionable

Receive CDY News and Ratings via Email

Sign-up to receive the latest news and ratings for CDY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Cellmid (ASX:CDY) Frequently Asked Questions

How were Cellmid's earnings last quarter?

Cellmid Limited (ASX:CDY) released its earnings results on Thursday, February, 21st. The company reported ($0.05) earnings per share (EPS) for the quarter.
View Cellmid's earnings history
.

Has Cellmid been receiving favorable news coverage?

Headlines about CDY stock have been trending positive recently, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Cellmid earned a news impact score of 2.1 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term.
View the latest news about Cellmid
.

Who are some of Cellmid's key competitors?

Who are Cellmid's key executives?

Cellmid's management team includes the following people:
  • Ms. Maria Halasz, CEO, MD & Exec. Director
  • Mr. Koichiro Koike, Managing Director of Advangen Inc (Age 62)
  • Dr. Graham Robertson, Head of R&D
  • Mr. Lee Tamplin, Company Sec.

What is Cellmid's stock symbol?

Cellmid trades on the ASX under the ticker symbol "CDY."

How big of a company is Cellmid?

Cellmid has a market capitalization of $0.00 and generates $7.65 million in revenue each year.

What is Cellmid's official website?

The official website for Cellmid is www.cellmid.com.au.

How can I contact Cellmid?

The company can be reached via phone at 61 2 9221 6830.

This page was last updated on 8/7/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.